Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

S. Gillessen, A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, P. S. Nelson, O. Sartor, M. R. Smith, H. R. Soule, H. Akaza, T. M. Beer, H. Beltran, A. M. Chinnaiyan, G. Daugaard, I. D. Davis, M. De Santis, C. G. Drake, R. A. Eeles, S. Fanti, M. E. Gleave, A. Heidenreich, M. Hussain, N. D. James, F. E. Lecouvet, C. J. Logothetis, K. Mastris, S. Nilsson, W. K. Oh, D. Olmos, A. R. Padhani, C. Parker, M. A. Rubin, J. A. Schalken, H. I. Scher, A. Sella, N. D. Shore, E. J. Small, C. N. Sternberg, H. Suzuki, C. J. Sweeney, I. F. Tannock & B. Tombal

[1]  S. Taneja.  Re: Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2016, The Journal of urology.

[2]  M. Cooperberg,et al.  Trans‐Pacific variation in outcomes for men treated with primary androgen‐deprivation therapy (ADT) for prostate cancer , 2016, BJU international.

[3]  M. Gleave,et al.  Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. , 2015, European urology.

[4]  C. V. von Klot,et al.  Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. , 2015, European urology.

[5]  S. Barni,et al.  Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series. , 2015, Clinical genitourinary cancer.

[6]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[7]  M. Parmar,et al.  Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). , 2015 .

[8]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[9]  P. Kantoff,et al.  Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Dearnaley,et al.  PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.

[11]  V. Conteduca,et al.  PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. , 2015, Clinical genitourinary cancer.

[12]  R. Berger,et al.  Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.

[13]  M. H. Poulsen,et al.  Spine metastases in prostate cancer: comparison of technetium‐99m‐MDP whole‐body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT , 2014, BJU international.

[14]  N. Agarwal,et al.  Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel , 2014, Prostate Cancer and Prostatic Disease.

[15]  Yan Liu,et al.  Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. , 2014, European journal of cancer.

[16]  D. Dearnaley,et al.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. , 2014, European urology.

[17]  E. Basch,et al.  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. , 2014, The Lancet. Oncology.

[18]  E. Antonarakis,et al.  Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone , 2014, The Prostate.

[19]  S. Hitier,et al.  792PTREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[21]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[22]  S. Oudard,et al.  Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.

[23]  V. Panebianco,et al.  Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy , 2014, BioMed research international.

[24]  R. DiPaola,et al.  Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[26]  D. Collins,et al.  Therapy monitoring of skeletal metastases with whole‐body diffusion MRI , 2014, Journal of magnetic resonance imaging : JMRI.

[27]  E. Crawford,et al.  Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. , 2014, Urology.

[28]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[29]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Collins,et al.  Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study , 2014, PloS one.

[31]  E. Crawford,et al.  Challenges and recommendations for early identification of metastatic disease in prostate cancer. , 2014, Urology.

[32]  N. Tunariu,et al.  Visceral disease in castration-resistant prostate cancer. , 2014, European urology.

[33]  A. McKenna,et al.  Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy , 2013, Prostate Cancer and Prostatic Disease.

[34]  P. Febbo,et al.  Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. , 2013, Radiology.

[35]  A. Partin,et al.  Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  F. Saad,et al.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Kantoff,et al.  The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer , 2013, Cancer.

[38]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[40]  A. Armstrong,et al.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Bono,et al.  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  I. Tannock,et al.  Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Rubello,et al.  Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.

[44]  J. Chen,et al.  Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[45]  N. Michoux,et al.  MRI for response assessment in metastatic bone disease , 2013, European Radiology.

[46]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[47]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[48]  E. Basch,et al.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. , 2012, The Lancet. Oncology.

[49]  J. Bono,et al.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[51]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[52]  H. Scher,et al.  Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. , 2012, European urology.

[53]  D. Tsavachidou,et al.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[55]  E. Crawford,et al.  A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. , 2011, The Journal of urology.

[56]  E. Small,et al.  Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response , 2011, Clinical Cancer Research.

[57]  D. Dearnaley,et al.  The CT flare response of metastatic bone disease in prostate cancer , 2011, Acta radiologica.

[58]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[59]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[60]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[61]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[62]  H. Akaza,et al.  Combined androgen blockade with bicalutamide for advanced prostate cancer , 2009, Cancer.

[63]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[64]  F. Saad,et al.  Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer , 2008, Cancer.

[65]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  D. Dearnaley,et al.  Detection of occult spinal cord compression with magnetic resonance imaging of the spine. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[68]  P. Therasse,et al.  Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases , 2005, The Prostate.

[69]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[70]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[72]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[73]  C. Catton,et al.  A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma , 2001, Cancer.

[74]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[75]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[76]  M. Gleave,et al.  Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience , 1998, European Urology.

[77]  P. Schellhammer,et al.  Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. , 1995, Urology.

[78]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[79]  K. Griffiths,et al.  Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. , 1991, British journal of urology.

[80]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[81]  D Ackman,et al.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[82]  C. Huggins,et al.  Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. , 1945, Annals of surgery.

[83]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[84]  Chia-Chien Hsu,et al.  The Delphi Technique: Making Sense of Consensus , 2007 .

[85]  I. Thompson,et al.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. , 2003, The Journal of urology.

[86]  T. Tosteson,et al.  Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. , 1997, Urology.

[87]  F. Labrie,et al.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. , 1982, Clinical and investigative medicine. Medecine clinique et experimentale.